New treatments for severe lung inflammation in older adults
Development of Novel Second Generation Anti-inflammatory Substrate-selective p38 MAP Kinase Inhibitors as Therapy for Acute Respiratory Distress Syndrome
This study is working on new medications to help people with Acute Respiratory Distress Syndrome (ARDS), especially those who have had respiratory infections like COVID-19, by creating drugs that can reduce harmful inflammation in the lungs while keeping the good stuff intact.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baltimore VA Medical Center NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11098473 on NIH RePORTER |
What this research studies
This research focuses on developing new medications to treat Acute Respiratory Distress Syndrome (ARDS), a serious condition that can occur after respiratory infections like COVID-19. The team is creating specialized inhibitors that selectively target specific pathways involved in inflammation, aiming to reduce the harmful effects of ARDS while preserving beneficial processes. By using advanced computer-aided drug design, they have identified promising compounds that may improve lung function and patient outcomes. The goal is to provide effective therapies for patients who currently have limited treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those over 65, who are at risk for or suffering from Acute Respiratory Distress Syndrome.
Not a fit: Patients who are younger than 65 or do not have risk factors for ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for ARDS, significantly improving survival rates and quality of life for affected patients.
How similar studies have performed: Other research has shown promise in targeting specific pathways in inflammation, suggesting that this approach could be effective, although it is still relatively novel.
Where this research is happening
Baltimore, United States
- Baltimore VA Medical Center — Baltimore, United States (Active)
Researchers
- Principal investigator: Hasday, Jeffrey D — Baltimore VA Medical Center
- Study coordinator: Hasday, Jeffrey D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.